Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma

International Journal of Cancer

Volumn 131, Issue 8, 2012, Pages 1930-1940

  Hui, K F ^a   Ho, Dona N ^a   Tsang, C M ^b   Middeldorp, Jaap M ^c   Tsao, George S W ^b   Chiang, Alan K S ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

apoptosis; Epstein Barr virus; lytic cycle; nasopharyngeal carcinoma; suberoylanilide hydroxamic acid

Indexed keywords

AZACITIDINE; BUTYRIC ACID; CASPASE 3; CASPASE 7; CASPASE 9; FOSCARNET; IMMEDIATE EARLY PROTEIN BZLF1; PHORBOL 13 ACETATE 12 MYRISTATE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BMRF1; TRICHOSTATIN A; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN 350; VIRUS PROTEIN; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA REPLICATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIFE CYCLE STAGE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 84865308897     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27439     Document Type: Article

References (29)

1. Rickinson AB, Kieff E,. Epstein-Barr virus, 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2007.
2. Tao Q, Chan AT,. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007; 9: 1-24. (Pubitemid 47398642)
3. Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, Rosato A,. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010; 95: 1769-77.
4. Feng WH, Hong G, Delecluse HJ, Kenney SC,. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004; 78: 1893-902. (Pubitemid 38176721)
5. Feng WH, Kenney SC,. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006; 66: 8762-9. (Pubitemid 44449193)
6. Feng WH, Westphal E, Mauser A, Raab-Traub N, Gulley ML, Busson P, Kenney SC,. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol 2002; 76: 10951-9. (Pubitemid 35176212)
7. Wang L, Shan L, Lo KW, Yin J, Zhang Y, Sun R, Zhong J,. Inhibition of nasopharyngeal carcinoma growth by RTA-expressing baculovirus vectors containing oriP. J Gene Med 2008; 10: 1124-33.
8. Hui KF, Chiang AK,. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int J Cancer 2010; 126: 2479-89.
9. Inman GJ, Binne UK, Parker GA, Farrell PJ, Allday MJ,. Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J Virol 2001; 75: 2400-10. (Pubitemid 32147578)
10. Matusali G, Arena G, De Leo A, Di Renzo L, Mattia E,. Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds. Mol Cancer 2009; 8: 18.
11. Foghsgaard L, Jaattela M,. The ability of BHRF1 to inhibit apoptosis is dependent on stimulus and cell type. J Virol 1997; 71: 7509-17. (Pubitemid 27391691)
12. Huang DP, Ho JH, Poon YF, Chew EC, Saw D, Lui M, Li CL, Mak LS, Lai SH, Lau WH,. Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer 1980; 26: 127-32. (Pubitemid 10086410)
13. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, Wen DS, Li YP,. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 1989; 86: 9524-8. (Pubitemid 20010459)
14. Fang CY, Lee CH, Wu CC, Chang YT, Yu SL, Chou SP, Huang PT, Chen CL, Hou JW, Chang Y, Tsai CH, Takada K, et al. Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. Int J Cancer 2009; 124: 2016-25.
15. Lui VW, Wong EY, Ho Y, Hong B, Wong SC, Tao Q, Choi GC, Au TC, Ho K, Yau DM, Ma BB, Hui EP, et al. STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer 2009; 125: 1884-93.
16. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM, Lee JC,. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999; 83: 121-6. (Pubitemid 29409487)
17. Amon W, Farrell PJ,. Reactivation of Epstein-Barr virus from latency. Rev Med Virol 2004; 15: 149-56. (Pubitemid 40675906)
18. Thompson MP, Kurzrock R,. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10: 803-21. (Pubitemid 38198878)
19. Al-Mozaini M, Bodelon G, Karstegl CE, Jin B, Al-Ahdal M, Farrell PJ,. Epstein-Barr virus BART gene expression. J Gen Virol 2009; 90: 307-16.
20. Martel-Renoir D, Grunewald V, Touitou R, Schwaab G, Joab I,. Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J Gen Virol 1995; 76 (Part 6): 1401-8.
21. Israel BF, Kenney SC,. Virally targeted therapies for EBV-associated malignancies. Oncogene 2003; 22: 5122-30. (Pubitemid 37059593)
22. Kawanishi M,. Epstein-Barr virus induces fragmentation of chromosomal DNA during lytic infection. J Virol 1993; 67: 7654-8. (Pubitemid 23343899)
23. Rodriguez A, Armstrong M, Dwyer D, Flemington E,. Genetic dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene product, Zta. J Virol 1999; 73: 9029-38. (Pubitemid 29487056)
24. Jung EJ, Lee YM, Lee BL, Chang MS, Kim WH,. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir. Cancer Lett 2007; 247: 77-83. (Pubitemid 44959412)
25. Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S,. The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol 2002; 76: 12503-12. (Pubitemid 35386936)
26. Mauser A, Holley-Guthrie E, Simpson D, Kaufmann W, Kenney S,. The Epstein-Barr virus immediate-early protein BZLF1 induces both a G(2) and a mitotic block. J Virol 2002; 76: 10030-7. (Pubitemid 35006543)
27. Chen YJ, Tsai WH, Chen YL, Ko YC, Chou SP, Chen JY, Lin SF,. Epstein-Barr Virus (EBV) Rta-mediated EBV and Kaposi's sarcoma-associated herpesvirus lytic reactivations in 293 cells. PLoS One 2011; 6: e17809.
28. Zuo J, Thomas W, van Leeuwen D, Middeldorp JM, Wiertz EJ, Ressing ME, Rowe M,. The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. J Virol 2008; 82: 2385-93. (Pubitemid 351293539)
29. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923-31. (Pubitemid 46218695)